Aspen Pharmacare, SA’s biggest pharmaceutical manufacturer, warned investors on Wednesday that the war in Ukraine poses direct and indirect threats to the business, adding to the pressures arising from the coronavirus pandemic.

While Aspen’s operations in Russia and Ukraine do not make a significant contribution to the group, the conflict is pushing up energy prices and putting pressure on already high inflation rates in Europe that could have knock-on effects on the wider business. The two countries generate R1bn in annual revenue, about 2% of the group’s total, said Aspen CEO Stephen Saad...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.